21 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
for approval. If and when those conditions have been met to the FDA’s satisfaction, the FDA will typically issue an approval letter. An approval letter … product candidates are safe and effective in treating patients to the satisfaction of the FDA;
results of clinical trials that may not meet the level
8-K
EX-99.1
MIRA
Mira Pharmaceuticals Inc
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
and uncertainties related to the satisfaction of customary closing conditions related to the public offering, or factors that result in changes to the Company’s
8-K
EX-99.2
2d8k183oho8
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
8-K
EX-1.1
54fuphp8i7 7fl91
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
8-K
EX-4.1
vcolkw3kl9zlicjsvd
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
424B4
krv7 pwje
4 Aug 23
Prospectus supplement with pricing info
1:01pm
424B1
w9222roo v7v2e9t
4 Aug 23
Prospectus with pricing info
12:59pm
S-1
53h20tr18jcidge
29 Jun 23
IPO registration
4:39pm
S-1
EX-10.2
18oxy1
29 Jun 23
IPO registration
4:39pm
S-1
EX-10.1
2zb4sdz 0bqs1pn1hm
29 Jun 23
IPO registration
4:39pm
DRS/A
cumq328y4czk6f
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
jf94i806e
2 May 23
Draft registration statement (amended)
12:00am